aztreonam has been researched along with B cepacia Infection in 5 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fischer, R | 1 |
| Schwarz, C | 1 |
| Weiser, R | 1 |
| Mahenthiralingam, E | 1 |
| Smerud, K | 1 |
| Meland, N | 1 |
| Flaten, H | 1 |
| Rye, PD | 1 |
| Barlow, G | 1 |
| Morice, A | 1 |
| Frost, F | 1 |
| Shaw, M | 1 |
| Nazareth, D | 1 |
| Tullis, DE | 1 |
| Burns, JL | 1 |
| Retsch-Bogart, GZ | 1 |
| Bresnik, M | 1 |
| Henig, NR | 1 |
| Lewis, SA | 1 |
| Lipuma, JJ | 1 |
| Balfour-Lynn, IM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Double-blind, Placebo-controlled Cross-over Study of Inhaled Alginate Oligosaccharide (OligoG) for 28 Days in Subjects With Cystic Fibrosis Using Aztreonam Due to Chronic Colonization With Burkholderia Spp.[NCT02453789] | Phase 2 | 15 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for aztreonam and B cepacia Infection
| Article | Year |
|---|---|
Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis.
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Aztreonam; Burkholderia cepacia complex; B | 2019 |
2 trials available for aztreonam and B cepacia Infection
| Article | Year |
|---|---|
Evaluating the alginate oligosaccharide (OligoG) as a therapy for Burkholderia cepacia complex cystic fibrosis lung infection.
Topics: Alginates; Aztreonam; Burkholderia cepacia complex; Burkholderia Infections; Cystic Fibrosis; Humans | 2022 |
Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Aztreonam; Burkholderia Infect | 2014 |
2 other studies available for aztreonam and B cepacia Infection
| Article | Year |
|---|---|
Successful treatment of resistant Burkholderia multivorans infection in a patient with cystic fibrosis using ceftazidime/avibactam plus aztreonam.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; Burkholderia; Bur | 2018 |
At last, Burkholderia spp. is one of the inclusion criteria--a negative (but published) randomised controlled trial.
Topics: Anti-Bacterial Agents; Aztreonam; Burkholderia Infections; Cystic Fibrosis; Female; Humans; Male | 2014 |